The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: A prospective, multicenter, open-label, single arm phase II study.
 
Takeshi Kato
Honoraria - Asahi Kasei; Bayer; Chugai Pharma; Lilly Japan; Merck Serono; Mochida Pharmaceutical Co. Ltd.; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Chugai Pharma
 
Masataka Ikeda
Consulting or Advisory Role - Daiichi Sankyo
Speakers' Bureau - Bayer; Chugai Pharma; Daiichi Sankyo; Lilly Japan; Merck Serono; Pfizer; Taiho Pharmaceutical
 
Atsuyo Ikeda
No Relationships to Disclose
 
Junichi Hasegawa
Honoraria - Chugai Pharma; Taiho Pharmaceutical
 
Hirofumi Ota
Honoraria - Chugai Pharma; Yakult Honsha
 
Tatsushi Shingai
Honoraria - Chugai Pharma; Lilly Japan; Otsuka; Sanofi; Taiho Pharmaceutical; Takeda
 
Masayoshi Yasui
Honoraria - Chugai Pharma; Daiichi Sankyo; Taiho Pharmaceutical
 
Hitoshi Fujii
Honoraria - Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Tsumura & Co.
 
Yasuhiro Miyake
Honoraria - Takeda
 
Mamoru Uemura
No Relationships to Disclose
 
Chu Matsuda
Honoraria - Chugai Pharma; Kaken Pharmaceutical; Lilly Japan; Tsumura & Co.; Yakult Honsha
 
Taroh Satoh
Honoraria - Astellas Pharma; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Lilly; Merck; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Bayer Yakuhin; Lilly; Merck Serono; Merck Serono; Nihonkayaku; Ono Pharmaceutical; Takara Bio
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Gilead Sciences (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Yakult Honsha (Inst)
 
Tsunekazu Mizushima
Research Funding - Astellas Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
 
Yuichiro Doki
Honoraria - Chugai Pharma; Yakult Honsha
Research Funding - Chugai Pharma; Yakult Honsha
 
Hidetoshi Eguchi
Research Funding - Chugai Pharma; Yakult Honsha